Open Science Summit 2011

Day I: Saturday, October 22

8:15 - 8:45 am
Keynote: Transparency in Scientific Discovery: Implications for Innovation and Knowledge Dissemination
Victoria Stodden

Abstract: Open Science is an inescapable part of scientific research. As computation assumes a central role in the practice of science, open science facilitates the reproducibility of published computational findings, promotes innovation in academia and in industry, and provides access to scientific knowledge beyond the ivory tower. In this talk I discuss the coming imperative of open science, and outline its implications for scientific integrity, the independent replication of results, the intellectual property framework for scientific knowledge, and public access to scientific knowledge.


8:45 - 9:45 am
Open Access, where we are, where we are going.
Nick Shockey, SPARC
Jill Cirasella, CUNY
Margaret Smith, NYU


9:45 – 10:00 am
Break


10:00 - 11:45 am
The Future (the End?) of “Intellectual Property”
Johanna Blakely
Ready to Share, Lessons from the fashion industry’s Free Culture

Stephan Kinsella
IP and the New Mercantilism

Andrew Torrance
Patents and Modern Biotechnology

Allen Black
The Fabyrzme Debacle, the Tragedy of Monopoly

11:45 am – 1:00 pm
Lunch


1:00 - 3:00 pm
This year in Open Science, Highlights from 2011
Joyce Peng, Beijing Genomics Institute
Crowd-Sourcing the Scientific Response to the E. Coli Outbreak

Peter Murray Rust

Daniel Meitchen
Wikimedia and Open Science

Dave Toole
Skolr poster session sharing software, DigitalOcean project

Anton Geraschenko
Math Overflow

Jai Rangathan
SciFund Challenge (Crowdfunding research)


Building an Open Science Business
Alex Hodgson
1degreeBio

Elizabeth Iorns
Sciencexchange

Carlo Rago, OpenOnward
WikiFormulation

Adam Regelmann
Quartzy


3:00 - 3:15 pm
Break


3:15 - 4:30 pm
Science Communication: Conveying the possibility of radical longevity breakthroughs to the public
Sonia Arrison
best selling author, 100+


Incentive Mechanisms for Collaborative Innovation
Jamie Love
Knowledge Ecology International

David Thompson
UCSF


4:45 - 5:45 pm
Open Innovation and Appropriate Technology
Gerald Barnett
Open Source 3D printing

Bryan Bishop
CAD and Open Hardware

Rob Meagley
Bootstrapping low cost instruments

Akhsar Kharebov
Open Source robotics and hardware

Day II: Open Medicine, Open Genomics, Clinical Trials 2.0

8:30 – 10:00 am
Personal Genomics, Hype, Hope, or Both?
Misha Angrist
the Personal Genome Project and patient empowerment

Rade Drmanac
co-founder Complete Genomics

David Ewing Duncan
Experimental Man, Personal Health Manifesto

Raymond McCauley
BioCurious, citizen science and really personal genomics

Jason Bobe
Personal Genome Project + Bioweathermaps


10:00 – 10:15 am
Break


10:15 am – 12:00 pm
Opening the Sources of Drug Discovery
Bernard Munos
Barry Bunin (Collaborative Drug Discovery)

Mat Todd
Open Source chemistry for neglected diseases

Barry Bunin
(Collaborative Drug Discovery)

David Shaywitz
Director of Strategic and Commercial Planning, Theravance


12:00 - 1:00 pm
Lunch


1:00 - 2:15 pm
Open Education and the Future of Science Education
Ingmar Riedel-Kruse and Rhiju Das
Biotechnology Games (eTeRNA, Fold It,”Biotec” games/Pacman Parmacia)

Alex Peake
Code Hero + Primer Labs

Mitch Altman
Noisebridge, Hacker Spaces and Education of the Future


2:15 – 2:30 pm
Break


2:30 - 3:30 pm
Life Sciences in the era of Big Data

Deepak Singh, Amazon EC2, Life Sciences in the Cloud

Ilya Kupershmidt, co-founder Next Bio

Joel Dudley, Numedii, Data Driven drug Repurposing


3:30 - 3:45 pm
Break


3:45 - 5:45 pm
Open Medicine and Clinical Trials 2.0
Tomasz Sablinski
Founder, CEO, Transparency Life Sciences

Lorenzo Albanello
Open medical data to improve personalized medicine

Marty Tenenbaum
Cancer Commons

Lindy Avey
Curious

Collection of in-depth patient phenotypic data in basic and clinical research presents significant challenges and may partly be one of the gating factors in advancing the field of personalized healthcare. Using the web and social networking tools, a new research paradigm is emerging that incorporates higher levels of patient involvement (Research 2.0) enabling prospective, dynamic engagement with the ‘experts’. How will drug development, testing, and approval as well as comparative medicine be able to embrace this shift in protocol design for a more progressive approach?

Marissa Nelson
23andMe

Nicole Boice
RARE Project, Global Genes Project, crowd-funding of rare diseases